168 related articles for article (PubMed ID: 7971442)
21. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis.
Bénard J; Bourhis J; de Vathaire F; Ferrandis E; Terrier-Lacombe MJ; Lemerle J; Riou G; Hartmann O
Prog Clin Biol Res; 1994; 385():111-6. PubMed ID: 7972202
[TBL] [Abstract][Full Text] [Related]
23. Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma.
Nakagawara A; Ikeda K; Higashi K; Sasazuki T
Surgery; 1990 Jan; 107(1):43-9. PubMed ID: 2404349
[TBL] [Abstract][Full Text] [Related]
24. Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
Brack T; Scholz RB; Milde-Langosch K; Heinsohn S; Löning T; Kabisch H
Cancer Detect Prev; 1992; 16(3):185-92. PubMed ID: 1458508
[TBL] [Abstract][Full Text] [Related]
25. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
26. [Sensibility and specificity of N-myc oncogene with respect to other prognostic factors in 15 neuroblastomas].
Queizán A; García-Miguel P; Belló MJ; Castresana JC; Rey JA; Pestaña A
Cir Pediatr; 1995 Jul; 8(3):96-8. PubMed ID: 8527322
[TBL] [Abstract][Full Text] [Related]
27. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
[TBL] [Abstract][Full Text] [Related]
29. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
[TBL] [Abstract][Full Text] [Related]
30. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
31. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
Amler LC; Schürmann J; Schwab M
Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
Zhang H; He X; Miao Q; Li L; Song J; Jiang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
[TBL] [Abstract][Full Text] [Related]
33. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
[TBL] [Abstract][Full Text] [Related]
34. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project.
Woods WG; Lemieux B; Tuchman M
Pediatrics; 1992 Jan; 89(1):114-8. PubMed ID: 1727993
[TBL] [Abstract][Full Text] [Related]
36. Biological characteristics of N-myc amplified neuroblastoma in patients over one year of age.
Nakagawara A; Ikeda K; Tsuda T; Higashi K
Prog Clin Biol Res; 1988; 271():31-9. PubMed ID: 3406005
[TBL] [Abstract][Full Text] [Related]
37. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei.
Valent A; Bénard J; Clausse B; Barrois M; Valteau-Couanet D; Terrier-Lacombe MJ; Spengler B; Bernheim A
Am J Pathol; 2001 May; 158(5):1579-84. PubMed ID: 11337354
[TBL] [Abstract][Full Text] [Related]
38. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
40. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]